• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Echo Therapeutics ramps up R&D spending during first quarter

Echo Therapeutics ramps up R&D spending during first quarter

May 18, 2010 By MassDevice staff

Echo Therapeutics pocketed some of its first licensing revenues ever during the first quarter but it was far from enough to overcome a hefty jump in operating expenses.

The Franklin, Mass.-based manufacturer of wireless, continuous-use glucose monitors said operating costs in the January-to-March quarter spiked 178 percent compared with the first quarter of 2009, reaching $2.4 million. Included in that rise was a $654,000, or 123 percent, increase in selling, general and administrative costs and an $1.1 million leap in research and development spending.

The higher R&D costs reported May 17 coincide Echo’s bid to branch out into additional business lines. The company is now partnering with the Ferndale Pharma Group to develop a device to deliver controlled dosages of lidocaine to the skin to control moderate pain. The companies recently began clinical trials of the device, with Ferndale expected to apply for 510(k) premarket notification pending a successful outcome of those trials.

Echo also began work in January on its Prelude SkinPrep System, essentially identical to the device now being tested by Ferndale and designed to deliver a variety of drugs through the skin using the company’s AzoneTS transdermal drug reformulation technology.

In a statement, Chief Executive Patrick Mooney said Echo is working on several internal initiatives intended to soon boost higher revenues, including an ongoing trial of its flagship Symphony glucose monitor. “We anticipate securing additional strategic partner licensing arrangements while we begin manufacturing scale-up for Prelude’s product validation and planned product launch in late 2010,” he said.

Licensing revenues for the quarter were $14,000 after Echo last year signed a pair of 10-year agreements that included certain non-refundable payments recognized during the first three months of 2010. Another $552,000 is expected to be recognized over the next 12 months, the company said.

Echo reported no revenues in the year-ago quarter.

Filed Under: Biotech, Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: Echo Therapeutics Inc.

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy